Virpax says CRADA with USAISR to evaluate Probudur extended to September 2024

Virpax Pharmaceuticals announced that the cooperative research and development agreement or CRADA with the U.S. Army Institute of Surgical Research or USAISR to evaluate Virpax’s Probudur, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024. The USASIR is the U.S. Department of Defense’s primary laboratory for developing solutions for trauma and critical care challenges in combat casualties. The trial, which was expected to start earlier this year, was slightly delayed due to a change in leadership at USAISR. LipoCure Rx , the manufacturer of the drug candidate, is preparing to ship the product and the trial is now expected to begin in the fourth quarter of this year. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours.